European Medicines Agency
www.ema.europa.eu
The European Medicines Agency's machine-readable website exports: the full register of 2,754 human and veterinary medicines assessed through the EU centralised procedure with their EMA product numbers, ATC codes, therapeutic indications, authorisation and opinion dates, plus live medicine supply shortages, orphan designations, paediatric investigation plans, safety referrals, PSUSA outcomes, direct healthcare professional communications, maximum residue limits, herbal monographs, scientific guidelines, news and events.
GET /v1/data/ema/dhpc1Request
curl "https://api.fastcrw.com/v1/data/ema/dhpc" \ -H "Authorization: Bearer $FASTCRW_API_KEY"
2Response example
A sample shape. Press Run to see live data from European Medicines Agency.
{
"meta": {
"total_records": 175,
"timestamp": "2026-10-21T18:05:37Z"
},
"data": [
{
"category": "Human",
"name_of_medicine": "Ocrevus",
"procedure_number": "EMA/VR/0000313041",
"active_substances": "ocrelizumab",
"dhpc_type": "Adverse event;Post-authorisation measure",
"regulatory_outcome": "Variation",
"referral_name": "",
"atc_code_human": "L04AG08",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Multiple Sclerosis",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "08/10/2026",
"first_published_date": "09/10/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/ocrevus"
},
{
"category": "Human",
"name_of_medicine": "Jentadueto",
"procedure_number": "",
"active_substances": "linagliptin;metformin hydrochloride",
"dhpc_type": "Quality defect",
"regulatory_outcome": "",
"referral_name": "",
"atc_code_human": "A10BD11",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Diabetes Mellitus, Type 2",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "20/08/2026",
"first_published_date": "20/08/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/jentadueto"
},
{
"category": "Human",
"name_of_medicine": "Litfulo",
"procedure_number": "",
"active_substances": "ritlecitinib tosilate",
"dhpc_type": "Adverse event;Post-authorisation measure;Restriction of indication",
"regulatory_outcome": "Variation",
"referral_name": "",
"atc_code_human": "L04AF08",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Alopecia Areata",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "10/08/2026",
"first_published_date": "10/08/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/litfulo"
},
{
"category": "Human",
"name_of_medicine": "Desogestrel / etonogestrel",
"procedure_number": "",
"active_substances": "desogestrel;etonogestrel",
"dhpc_type": "Adverse event;Post-authorisation measure",
"regulatory_outcome": "Variation",
"referral_name": "",
"atc_code_human": "",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "06/08/2026",
"first_published_date": "06/08/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/desogestrel-etonogestrel"
},
{
"category": "Human",
"name_of_medicine": "Vyvgart",
"procedure_number": "",
"active_substances": "efgartigimod alfa",
"dhpc_type": "Quality defect",
"regulatory_outcome": "",
"referral_name": "",
"atc_code_human": "L04AA58",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Myasthenia Gravis;Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "23/07/2026",
"first_published_date": "24/07/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/vyvgart"
},
{
"category": "Human",
"name_of_medicine": "Tavneos",
"procedure_number": "EMA/REF/0000325221",
"active_substances": "avacopan",
"dhpc_type": "Referral - Article 20 procedure",
"regulatory_outcome": "Revocation",
"referral_name": "Tavneos",
"atc_code_human": "L04",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Microscopic Polyangiitis;Wegener Granulomatosis",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "16/07/2026",
"first_published_date": "17/07/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/tavneos"
},
{
"category": "Human",
"name_of_medicine": "Ixchiq",
"procedure_number": "",
"active_substances": "Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated",
"dhpc_type": "Adverse event;Restriction of indication",
"regulatory_outcome": "Variation",
"referral_name": "Ixchiq",
"atc_code_human": "J07BP01",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Chikungunya virus",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "14/07/2026",
"first_published_date": "14/07/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/ixchiq-1"
},
{
"category": "Human",
"name_of_medicine": "Evrysdi",
"procedure_number": "",
"active_substances": "risdiplam",
"dhpc_type": "Quality defect",
"regulatory_outcome": "",
"referral_name": "",
"atc_code_human": "M09AX10",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Muscular Atrophy, Spinal",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "12/06/2026",
"first_published_date": "22/06/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/evrysdi-0"
},
{
"category": "Human",
"name_of_medicine": "Tecovirimat SIGA",
"procedure_number": "EMA/REF/0000287477",
"active_substances": "tecovirimat monohydrate",
"dhpc_type": "Restriction of indication",
"regulatory_outcome": "Variation",
"referral_name": "Tecovirimat SIGA",
"atc_code_human": "J05AX24",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Poxviridae Infections;Cowpox;Monkeypox;Vaccinia;Smallpox",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "11/05/2026",
"first_published_date": "13/05/2026",
"last_updated_date": "13/05/2026",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/tecovirimat-siga"
},
{
"category": "Human",
"name_of_medicine": "Ontozry",
"procedure_number": "",
"active_substances": "cenobamate",
"dhpc_type": "Adverse event;Post-authorisation measure",
"regulatory_outcome": "Variation",
"referral_name": "",
"atc_code_human": "N03AX",
"atcvet_code_veterinary": "",
"therapeutic_area_mesh": "Epilepsy",
"species": "",
"other_related_medicines_nationally_authorised": "",
"dissemination_date": "12/05/2026",
"first_published_date": "13/05/2026",
"last_updated_date": "",
"dhpc_url": "https://www.ema.europa.eu/en/medicines/dhpc/ontozry"
},
"… 165 more items"
]
}Attribution: Source: European Medicines Agency (EMA), www.ema.europa.eu - reproduced under EMA's limited reproduction notice
Licence: EMA's Legal notice, under "European Medicines Agency copyright and limited reproduction notices", states: "The contents of these webpages are (c) EMA [1995-2026]. In particular, unless otherwise stated or unless indicated by EMA following the required consultation set out below, EMA is the owner of copyright and other intellectual property rights for documents and other content published on this website. This is according to current European Union and international legislation. Information and documents made available on EMA's webpages are public and may be reproduced and / or distributed, totally or in part, irrespective of the means and / or the formats used, for non-commercial and commercial purposes, provided that EMA is always acknowledged as the source of the material. Such acknowledgement must be included in each copy of the material. Citations may be made from such material without prior permission, provided the source is always acknowledged. The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder. The above-mentioned permissions also do not apply to photos or other materials that are not under the copyright of EMA." The EMA logo is carved out: "The European Medicines Agency logo is the exclusive property of the European Medicines Agency. Its use is prohibited without our prior written permission." Citation format asked for: "To cite material from the EMA's website, please list it with the URL, and the month and year you accessed it." The same site's Disclaimer adds: "EMA accepts no responsibility or liability whatsoever ... arising out of, or in connection with, the information on this site", that the information is "not necessarily comprehensive, complete, accurate or up to date" and is "not professional or legal advice", and that "it cannot be guaranteed that a document available online reproduces an officially adopted text precisely. Thus, in case of disagreement, the official adopted text will always prevail." The JSON files themselves are published for exactly this use: "You can download structured JSON data files to automatically access and retrieve up-to-date information and documents from the European Medicines Agency's (EMA) website. These data files specifically target use via automated systems."
Ask with this source
A prompt for your agent that names this source and how to call it through the crw MCP.
Direct healthcare professional communications
Use European Medicines Agency (ema) from fastCRW Pergamon, capability "Direct healthcare professional communications" (dhpc). You need the EU's urgent prescriber safety warnings for a medicine, or the latest DHPCs issued. Use the crw MCP tools: crw_find_data to confirm the source and its options, then crw_get_data with provider "ema" and capability "dhpc". Tell me the credits used and cite the licence from the response. If the crw MCP tools are missing, install them with: npx -y crw-mcp install --api-key <your fastCRW API key>
EMA events calendar
Use European Medicines Agency (ema) from fastCRW Pergamon, capability "EMA events calendar" (events). You need EMA committee meetings, workshops or public hearings and their dates. Use the crw MCP tools: crw_find_data to confirm the source and its options, then crw_get_data with provider "ema" and capability "events". Tell me the credits used and cite the licence from the response. If the crw MCP tools are missing, install them with: npx -y crw-mcp install --api-key <your fastCRW API key>
Guidance and information pages
Use European Medicines Agency (ema) from fastCRW Pergamon, capability "Guidance and information pages" (guidance-pages). You want to find or crawl EMA's explanatory and procedural pages rather than its structured registers. Use the crw MCP tools: crw_find_data to confirm the source and its options, then crw_get_data with provider "ema" and capability "guidance-pages". Tell me the credits used and cite the licence from the response. If the crw MCP tools are missing, install them with: npx -y crw-mcp install --api-key <your fastCRW API key>
Herbal substance monographs
Use European Medicines Agency (ema) from fastCRW Pergamon, capability "Herbal substance monographs" (herbal-medicines). You are checking whether a herbal substance has an EU monograph and what the HMPC concluded about it. Use the crw MCP tools: crw_find_data to confirm the source and its options, then crw_get_data with provider "ema" and capability "herbal-medicines". Tell me the credits used and cite the licence from the response. If the crw MCP tools are missing, install them with: npx -y crw-mcp install --api-key <your fastCRW API key>